Coronavirus spike glycoprotein receptor binding domains and uses thereof
By replacing amino acids in the RBD and SD1 of the coronavirus spike glycoprotein, a recombinant polypeptide with enhanced thermal stability and antigenicity is formed, which solves the problem of unstable binding between RBD and ACE2 in existing vaccines and achieves more efficient neutralizing antibody efficacy and immunogenicity.
Patent Information
- Application Number
- CN202480040845.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-11-14
- Filing Date
- 2024-05-10
- Publication Date
- 2026-02-24
AI Technical Summary
Existing coronavirus vaccines have shortcomings in improving their properties, particularly the unstable binding of the receptor-binding domain (RBD) of the SARS-CoV-2 viral spike glycoprotein to the ACE2 receptor, which affects the effectiveness of neutralizing antibodies.
A recombinant peptide containing the antigenic fragment RBD of the coronavirus spike glycoprotein and the optional coronavirus subdomain SD1 was designed. The thermal stability and antigenicity of the peptide were improved by performing polar amino acid substitutions at specific amino acid positions, and the peptide was assembled with a protein nanostructure to form a self-assembled protein nanostructure.
It enhances the binding ability of peptides to ACE2 receptors, improves the efficacy of neutralizing antibodies, and enhances immunogenicity and thermal stability through self-assembled protein nanostructures, making it suitable for a variety of coronavirus strains.